Antiamoebic properties of the actinomycete metabolites echinomycin A and tirandamycin A
- 5 July 2012
- journal article
- research article
- Published by Springer Nature in Parasitology Research
- Vol. 111 (6) , 2473-2477
Abstract
Entamoeba histolytica infects 50 million people per year, causing 100,000 deaths worldwide. The primary treatment for amoebiasis is metronidazole. However, increased pathogen resistance combined with the drug’s toxic side effects encourages a search for alternative therapeutic agents. Secondary metabolites from marine bacteria are a promising resource for antiprotozoan drug discovery. In this study, extracts from a collection of marine-derived actinomycetes were screened for antiamoebic properties, and the activities of antibiotics echinomycin A and tirandamycin A are shown. Both antibiotics inhibited the in vitro growth of a E. histolytica laboratory strain (HM-1:IMSS) and a clinical isolate (Colombia, Col) at 30- to 60-μM concentrations. EIC50 (estimated inhibitory concentration) values were comparable for both antibiotics (44.3–46.3 μM) against the E. histolytica clinical isolate.Keywords
This publication has 33 references indexed in Scilit:
- Tirandamycins from Streptomyces sp. 17944 Inhibiting the Parasite Brugia malayi Asparagine tRNA SynthetaseOrganic Letters, 2011
- Reassessment of the epidemiology of amebiasis: State of the artInfection, Genetics and Evolution, 2009
- Effects of iron depletion on Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) and trophozoite growth: implications for antiamoebic therapyJournal of Antimicrobial Chemotherapy, 2009
- Marine Actinomycetes: A New Source of Compounds against the Human Malaria ParasitePLOS ONE, 2008
- Current Therapeutics, Their Problems, and Sulfur-Containing-Amino-Acid Metabolism as a Novel Target against Infections by “Amitochondriate” Protozoan ParasitesClinical Microbiology Reviews, 2007
- Developing a new resource for drug discovery: marine actinomycete bacteriaNature Chemical Biology, 2006
- Bioactive Microbial MetabolitesThe Journal of Antibiotics, 2005
- Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecyclineDiagnostic Microbiology and Infectious Disease, 2004
- Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) as a target for anti-amoebic agentsJournal of Antimicrobial Chemotherapy, 2004
- In Vitro Metronidazole and Tinidazole Activities against Metronidazole- Resistant Strains of Trichomonas vaginalisAntimicrobial Agents and Chemotherapy, 2003